Research programme: globoid cell leukodystrophy therapy - ShireAlternative Names: HGT-2610
Latest Information Update: 12 Nov 2016
At a glance
- Originator Shire
- Class Enzymes
- Mechanism of Action Enzyme replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Globoid cell leukodystrophy
Most Recent Events
- 18 Nov 2008 Preclinical trials in Globoid cell leukodystrophy in United Kingdom (Parenteral)